Recruitment support for COVID-19 trials

Since the early days of the COVID-19 Pandemic Clariness has been engaged in supporting multiple clinical trial protocols in this completely new and challenging clinical research area.  

Clariness recruited patients for multiple protocols, including patients who have been tested positive for
SARS-CoV-2 by PCR, patients who are only experiencing COVID-19 symptoms as well as first-line-responder professionals (e.g. health care professionals, policemen, firefighters).

Clariness conduct of patient insight surveys in more than 17,000 patients in 21 countries, protocol feasibility studies as well as active recruitment for clinical trials.

Clariness is actively supporting three clinical trials for the Treatment of COVID-19 patients.

  • This program includes >100 research sites across North America.
  • As of today, Clariness’ Active Recruitment Campaign has contributed >750 consented and 650 randomized patients, which is equivalent to more than 25% of overall contribution and will support achieving recruitment ahead of plan
  • Clariness is responsible for the end-to-end campaign management from patient engagement to patient pre-screening and referral management as well as the intensified site management including site evaluation and optimization
  • Clariness continues to be active in the recruitment of patients who have been tested positive for
    SARS-CoV-2 by PCR within 72hrs prior to randomization to receive an active treatment. We are successfully identifying and pre-screening patients with positive tests in time to be screened at site, as well as symptomatic patients who have yet to have a test (for sites that are capable and willing to testing patients)


How COVID-19 Is Impacting Clinical Trials

Clariness has conducted a Global Direct Patient Insight Survey in

  • >500,000 contacts in 21 countries (EU, NA, SA, APAC, ROW)
  • >17,000 complete responders
  • >10,000 (62%) patients with chronic diseases in all major TAs as well as healthy participants and patients currently or previously participating in a clinical trial (N>3,900).


This survey helped us to develop a fundamental understanding of:

  • Patient’s willingness to continue participation in ongoing clinical trials.​
  • Patient’s willingness to newly participate in a clinical trial​.
  • Patient’s willingness to newly participate in COVID-19 clinical trials. ​


Our Approach to Your Project

Combining Digital Approach, Patient Understanding & Site Engagement



In case you or your team need support in one of your projects in COVID-19

or have any questions, please feel free to reach out to

Dr. Andree Beckerling | CEO
Mobile: +49 (0) 173 510 40 13
[email protected]

The CLARINESS Team is here to help YOU overcome the challenges during this extraordinary time.